Camilla Rega

Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer

M. Dowsett, S. Johnston, T. Bihani, 2022, npj Breast Cancer.

PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance

A. Vincent-Salomon, S. Vacher, A. Nicolas, 2020, Nature Communications.